

**10th September 2019**

**Nuformix plc**  
("Nuformix" or "the Group"),

**Resignation of Kirk Siderman-Wolter**

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces the resignation of Kirk Siderman-Wolter from the Nuformix Board of Directors with immediate effect. The resolution to re-elect Kirk Siderman-Wolter as a Director of the Company at the Annual General Meeting to be held at 1pm today will now be withdrawn from the meeting.

**Dr Dan Gooding, CEO, Nuformix plc, said:** *"On behalf of the Board and the Company, I would like to thank Kirk for his work and commitment to the Board and the Company during his tenure, a period of tremendous growth and change for the Company. The Board would like to wish Kirk well in his future endeavours."*

*Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.*

**Enquiries:**

<b>Nuformix plc</b>	+44 (0)1223 627222
<b>Dr Dan Gooding, Chief Executive Officer</b>	
<b>Optimum Strategic Communications</b>	+44 (0) 20 3950 9144
<b>Mary Clark, Supriya Mathur</b>	
<b>Email: <a href="mailto:nuformix@optimumcomms.com">nuformix@optimumcomms.com</a></b>	

**About Nuformix plc [www.nuformix.com](http://www.nuformix.com)**

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix's IP portfolio of granted patents covers cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END